Loading organizations...
§ Private Profile · Samone, Emilia-Romagna, Italy
Clinical-stage biotechnology company developing drugs for dermatology, inflammation, and pain, focused on topical TrkA kinase inhibitors.
Creabilis SA is a Luxembourg City, Luxembourg-based clinical-stage biotechnology company that develops topical drugs to treat conditions in dermatology, inflammation, and pain management. The organization focuses on creating topical TrkA kinase inhibitors, advancing a pipeline that includes CT327 for psoriasis and atopic dermatitis, alongside CT340 and CT637 for various inflammatory conditions. Prior to its exit, the business secured significant venture capital financing, including a $20 million Series B round in October 2011 led by Abbott Biotech Ventures, with participation from Sofinnova Partners and NeoMed. Creabilis ultimately reached a reported total funding amount of $1.5 billion before being acquired by Sienna Labs in December 2016 for an upfront payment of approximately $150 million plus additional milestones. The exact founding year and the identities of the original founders of the enterprise are not publicly known.
Creabilis has raised $19.9M across 1 funding round.
Creabilis has raised $19.9M in total across 1 funding round.
Creabilis has raised $19.9M across 1 funding round. Most recently, it raised $19.9M Series B in October 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 4, 2011 | $19.9M Series B | Abbott Biotech Ventures | Neomed Management, Sofinnova Partners | Announced |
Creabilis has raised $19.9M in total across 1 funding round.
Creabilis's investors include Abbott Biotech Ventures, NeoMed Management, Sofinnova Partners.